002422 Sichuan Kelun Pharmaceutical
- 31.40
- -1.19-3.65%
Sichuan Kelun Pharmaceutical News
Colon Pharmaceutical: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Colon Pharmaceuticals: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2024
Colon Pharmaceuticals: Announcement on changes in the company\'s registered capital and amendments to the company\'s articles of association
Colon Pharmaceuticals: 2024 Semi-Annual Financial Report
Colon Pharmaceuticals: Announcement on Subsidiary Bupivacaine Liposomal Injection Obtaining Drug Registration Approval
Sichuan Kelun Pharmaceutical: Announcement Regarding the Acceptance of New Drug Application for Subsidiary's Core Pharmaceutical, Sac-TMT (Lukang Satuximab Monotherapy), by National Medical Products Administration.
Sichuan Kelun Pharmaceutical: Announcement Regarding Progress of Cooperation between Controlling Subsidiary KELUN-BETTER Pharmaceuticals and Merck.
Sichuan Kelun Pharmaceutical: Announcement on changing the continuously supervised sponsoring representative.
Sichuan Kelun Pharmaceutical: Announcement on the pharmaceutical registration approval of subsidiary's injections of meropenem and sodium chloride injection.
Sichuan Kelun Pharmaceutical: Announcement on the approval of the clinical trial application of pharmaceutical injection SKB518 for innovative drugs of a subsidiary by the National Medical Products Administration.
Sichuan Kelun Pharmaceutical: Announcement on the subsidiary's core product, lucan satuzumab (sAC-TMT), announcing research results at the 2024 American Society of Clinical Oncology Annual Meeting
Sichuan Kelun Pharmaceutical: Announcement on applying for liability insurance for company directors, supervisors and senior management
Sichuan Kelun Pharmaceutical: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: Legal Opinion of Colon Pharmaceuticals 2023 Annual General Meeting of Shareholders
Sichuan Kelun Pharmaceutical: Announcement on the results of the election of the company's employee representatives and supervisors for a new term
Sichuan Kelun Pharmaceutical: Announcement on the subscription for domestic shares issued by the holding subsidiary Collumbotai
Colon Pharmaceuticals: Internal Control Self-Assessment Report
Colon Pharmaceutical: Report on the fiduciary management affairs of the public issuance of convertible corporate bonds by Sichuan Colon Pharmaceutical Co., Ltd. (2023)
Colon Pharmaceuticals: Shareholder Return Plan for the Next Three Years (2024-2026)
Colon Pharmaceuticals: Notice of Annual General Meeting of Shareholders
Analysis
Price Target
No Data
